archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Recent news: Endeavour establishes largest medtech fund in Europe at EUR 250m
    Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing August 19 2014 New Dundee studio for Kobojo July 22 2014 CommProve strengthen its commitment with Cell C in Africa July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant June 12 2014 Amplidata Expands Leadership Team to Support Growth June 11 2014 Amplidata Reaches New Heights In Storage Scalability and Manageability with Himalaya June 11 2014 Verizon Adopts Amplidata s New Himalaya Storage Architecture for Cloud Storage Service April 29 2014 Amplidata and Avere Systems Redefine The Economics Of Massively Scalable High Performance NAS Storage April 25 2014 Mutants Genetic Gladiators Brings Monster Battles to iOS Android Platforms April 10 2014 CommProve confirm its strong presence in LATAM April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 24 2014 Amplidata Secures 11M to Drive Next Phase of Growth March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 22 2014 Sakura Internet Cloud Datacenter Deploys Amplidata Object Store for Cloud Archiving Backup and Content Delivery Services January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments December 2 2013 Blackhawk Network Acquires Germany Based Prepaid Leader Retailo as Part of Ongoing International Expansion Strategy November 19 2013 Spartoo test driver of the European Google Trusted Store program November 13 2013 Amplidata Named a Leader in IDC MarketScape for Object Based Scale Out Storage October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time October 8 2013 CommProve Announces New Mobile Operator Win in Asia September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 18 2013 CommProve Wins 2 7M New Business in Africa September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA

    Original URL path: http://www.endeavourvision.com/news-m26-current+news.htm (2016-04-25)
    Open archived version from archive


  • Recent news: Merz Pharma takes over Swiss dermatology specialist Neocutis
    Max Levchin Joins Board July 19 2011 Paper li THE BLOG One Billion Articles Featured by Paperli Publishers June 1 2011 Retailo kauft die giftmobile GmbH und komplettiert so das Angebot May 26 2011 Ex Electronic Arts Executive Gerhard Florin joins Kobojo May 20 2011 CommProve releases real time RAN congestion management solution May 19 2011 Sequans Ships Ten Millionth 4G Chip May 18 2011 Symetis reports on its trans apical ACURATE TA clinical May 4 2011 Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases April 28 2011 Molecular Partners reports positive results from its first clinical studies April 26 2011 Kobojo completes the first round of its 7 5 million 5 3 million fund raising programme with Endeavour Vision and IDinvest Partners April 15 2011 Sequans Communications Announces Pricing of Initial Public Offering April 12 2011 Amplidata and ReelData join forces to enable scalable active archive solutions for media and entertainment April 6 2011 BIND Biosciences Receives 2011 Edison Award April 5 2011 Amplidata introduces AmpliStor optimized object storage for massive scale unstructured data February 16 2011 Interview with Lars Pedersen February 15 2011 BroadHop and CommProve Team to Deliver Industry s First End to End Intelligent Application and Subscriber RAN Congestion Management February 15 2011 Nfocus Neuromedical Inc Luna Aneurysm Embolization System Receives CE Mark February 14 2011 CommProve and 2operate partner to provide powerful network troublehsooting solution February 11 2011 BIND Biosciences featured in the London Times February 8 2011 Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech Inc in Immunology to Develop Multispecific DARPins January 13 2011 Amplidata Attacks U S and World Cloud Market with AmpliStor January 11 2011 SmallRivers Announces 2 1M Financing Round to Expand Paper li Globally January 7 2011 BIND Biosciences Initiates Phase 1 Clinical Study of BIND 014 January 4 2011 PneumRx Inc Raises 33 Million in Capital December 7 2010 Retailo coverage on BR Germany December 1 2010 Mobile Europe Year End Special Edition November 30 2010 Amplidata Tech Tour Finalist November 15 2010 Endotis Pharma reports successful completion of the neutralization study of the anticoagulant EP217609 by avidin in healthy subjects November 10 2010 CommProve and Qosmos partner to analyze data performance problems in mobile carrier networks October 19 2010 CommProve secures additional financing to fund organic and non organic growth October 7 2010 Symetis closes CHF 25 million financing led by Endeavour Vision and NBGI Ventures Eric Milledge appointed Chairman of the Board October 1 2010 Retailo wins the prestigious September 16 2010 Amplidata closes 6m funding round sees big future for unbreakable storage September 14 2010 Veebeam is launched in the US and Europe September 1 2010 Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum June 29 2010 BIND Biosciences Secures 12 4 Million Financing June 2 2010 Kuros completes patient recruitment in Phase IIb study of KUR 113 in patients with tibial shaft fractures April 8 2010 Serge Blanco extends item level visitbility to retail store with Tagsys RFID March 16 2010 Sequans Announces First LTE chip March 16 2010 TAGSYS secures 8 million in venture funding March 15 2010 Kuros meets primary efficacy endpoint in Phase IIb study with KUR 111 February 1 2010 Germany Switzerland Austria Spain Netherlands Belgium Retailo third party prepaid card network expanding in Europe January 13 2010 Spartoo com secures 12 million in funding to accelerate European growth December 23 2009 Andor Technology Acquires Bitplane December 15 2009 Molecular Partners Secures CHF 46 Million in a Series B Financing December 3 2009 Sequans Selected by China Mobile to Supply TD LTE Chips November 18 2009 Sequans Secures Funding from Alcatel Lucent and Motorola Ventures for LTE Development October 7 2009 CeQur SA Appoints Eric Milledge Chairman of the Board of Directors August 27 2009 Lumavita AG announces Marketing Authorisation for Pentamycin in Switzerland August 12 2009 Kuros announces encouraging Phase IIa data with KUR 212 in patients with burns requiring mesh grafting August 10 2009 SaaS Model Sees Growing Demand Overseas July 23 2009 Daptiv Brings Kevin Hickey on Board as Chairman of the Board of Directors July 13 2009 NovImmune successfully completes NI 0801 Phase I clinical study July 7 2009 Kuros starts Phase IIb clinical trial with DUR 211 for diabetic foot ulcers June 18 2009 Lumavita AG announces new funding June 16 2009 Virtutech Simics used to develop Wind River Hypervisor and secure VxWorks MILS Platform June 15 2009 Freescale speeds embedded multicore adoption with new VortiQa software products and an expanded ecosystem June 8 2009 Kuros Completes patient recruitment in a phase IIb trial of KUR 111 in patients with tibal plateau fractures June 2 2009 Sequans Ships its Millionth WiMAX Chip May 19 2009 Endotis Pharma reports successful completion of phase I program with EP42675 a first in class synthetic parenteral anticoagulant May 19 2009 Cadence and Virtutech Extend Metric Driven Verification to Virtual Systems Development May 12 2009 NovImmune completes CHF 62 5 USD 54 8 million equity financing to move portfolio forward and reacquire product rights to lead antibodies April 18 2009 Ignis ASA has today signed an agreement to acquire Syntune AB April 1 2009 Seventure Wellington and Endeavour invest 7m into Retailo AG March 30 2009 Perigee reprend les activités Satin et Catalliances March 24 2009 Lumavita AG announces receipt of Preliminary Approval for Marketing Authorisation of pentamycin in Switzerland for the treatment of February 27 2009 Novalar Announces the Launch of OraVerse the First Dental Anesthesia Reversal Agent February 23 2009 NASA Selects Virtutech Simics Virtual Platform for Orion February 17 2009 TAGSYS Names Alain Fanet as Chief Executive Officer January 16 2009 Sequans Communications Achieves First Pass Silicon Success With Synopsys DesignWare USB 2 0 nanoPHY IP January 9 2009 Retailo and Lekkerland Sign a Partnership Agreement for Giftcard Distribution January 5 2009 CeQur SA Completes Series A Investment with 10 Million Dollar Raise in December 2009 November

    Original URL path: http://www.endeavourvision.com/news-m27-archive.htm (2016-04-25)
    Open archived version from archive

  • Endeavour Vision
    for Endeavour Vision is to the right of the C A department store we are on the 6th floor contact for limited partners Endeavour Medtech GP Ltd IPES Guernsey Limited 1 Royal Plaza Royal Avenue St Peter Port Guernsey GY1 2HL United Kingdom endeavour ipes com Open in Google Maps Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms very quick They are highly professional partners and support us in every possible manner Christian Lindner Co Founder and CEO Retailo AG We wanted a Venture Capital investor who was prepared to share our vision to create a global European company The quality of their track record the way they are helping us

    Original URL path: http://www.endeavourvision.com/info-29-11-contact.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Endeavour establishes largest medtech fund in Europe at EUR 250m
    Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing August 19 2014 New Dundee studio for Kobojo July 22 2014 CommProve strengthen its commitment with Cell C in Africa July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant June 12 2014 Amplidata Expands Leadership Team to Support Growth June 11 2014 Amplidata Reaches New Heights In Storage Scalability and Manageability with Himalaya June 11 2014 Verizon Adopts Amplidata s New Himalaya Storage Architecture for Cloud Storage Service April 29 2014 Amplidata and Avere Systems Redefine The Economics Of Massively Scalable High Performance NAS Storage April 25 2014 Mutants Genetic Gladiators Brings Monster Battles to iOS Android Platforms April 10 2014 CommProve confirm its strong presence in LATAM April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 24 2014 Amplidata Secures 11M to Drive Next Phase of Growth March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 22 2014 Sakura Internet Cloud Datacenter Deploys Amplidata Object Store for Cloud Archiving Backup and Content Delivery Services January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments December 2 2013 Blackhawk Network Acquires Germany Based Prepaid Leader Retailo as Part of Ongoing International Expansion Strategy November 19 2013 Spartoo test driver of the European Google Trusted Store program November 13 2013 Amplidata Named a Leader in IDC MarketScape for Object Based Scale Out Storage October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time October 8 2013 CommProve Announces New Mobile Operator Win in Asia September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 18 2013 CommProve Wins 2 7M New Business in Africa September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA

    Original URL path: http://www.endeavourvision.com/news-n267-c0-Endeavour+establishes+largest+medtech+fu.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Sophia Genetics reaches milestone to become the global leader in precision medicine, connecting over 100 hospitals and laboratories to form the world’s largest clinical genomics community for molecular diagnosis
    of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Sophia Genetics has risen to become the global leader in precision medicine now supporting over 100 healthcare institutions around the world to form the world s largest clinical genomics community Sophia s platform Sophia DDM is a software as a service platform designed to perform routine diagnostic testing with an emphasis on genomic analysis and machine learning to help clinicians more quickly and accurately diagnose some common cancers and inherited conditions Sophia DDMTM enables secure knowledge sharing between clinical genomics experts unlocking the immediate benefits of precision medicine for patients Since its launch in April 2014 Sophia s cutting edge platform has supported the diagnosis of over 25 000 patients in Europe and a

    Original URL path: http://www.endeavourvision.com/news-n266-c0-s22-Sophia+Genetics+reaches+milestone+to+bec.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Molecular Partners 1H 2015 Release
    of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Zurich Schlieren September 02 2015 Molecular Partners AG ticker symbol MOLN announced today its results for the first half year 2015 which proved to be a successful and dynamic semester for Molecular Partners from multiple perspectives significant advancement of the pipeline important strengthening of the team clarity and stability obtained in the key strategic partnership with Allergan as well as further reinforcement of the company s strong financial position Molecular Partners CEO Christian Zahnd summarizes Our achievements during the first six months of 2015 put us in a very robust position within the biotech sector I am especially pleased about the substantial progress we made in our pipeline and that we were able to

    Original URL path: http://www.endeavourvision.com/news-n265-c0-s22-Molecular+Partners+1H+2015+Release.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Symetis announces intention to float on SIX Swiss Exchange
    15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Lausanne Ecublens Switzerland September 1 2015 Symetis SA a leading Swiss medical technology company focused on transcatheter aortic valve implantation TAVI announced today its intention to float its shares and list on SIX Swiss Exchange in 2015 Proceeds from the initial public offering IPO will enable the company to accelerate and expand its commercial activities in the EU strengthen its proprietary product pipeline and technology platform as well as expand its activity in Asia and the United States TAVI is a lifesaving minimally invasive treatment indicated for patients suffering from severe aortic stenosis who are deemed too high a risk to undergo a standard open heart surgical aortic valve replacement TAVI is principally performed through two different

    Original URL path: http://www.endeavourvision.com/news-n264-c0-s22-Symetis+announces+intention+to+float+on+.htm (2016-04-25)
    Open archived version from archive

  • Recent news: CeQur Announces $100 Million Series C Financing
    Molecular Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Funds will facilitate ongoing clinical and regulatory activities as well as commercial scale up for the world s first three day simple insulin infusion device for type 2 diabetes World class management team expedites fully optimized second generation device as a superior alternative to injection therapy LUCERNE Switzerland and MARLBOROUGH Mass 1 September 2015 CeQur SA CeQur or the Company a leader in simple insulin infusion for people with diabetes today announced a Series C financing of 100 million The financing will support further clinical and regulatory activities manufacturing scale up and commercial operations for the 2016 first commercial launch of PaQ the Company s fully optimized second generation three

    Original URL path: http://www.endeavourvision.com/news-n263-c0-s22-CeQur+Announces+%24100+Million+Series+C+.htm (2016-04-25)
    Open archived version from archive



  •